Chemocentryx Enterprise Value over EBITDA Trend from 2010 to 2021

CCXI -  USA Stock  

USD 17.19  0.11  0.64%

Chemocentryx Enterprise Value over EBITDA is decreasing over the last several years with slightly volatile swings. Enterprise Value over EBITDA is predicted to flatten to -88.11. During the period from 2010 to 2021 Chemocentryx Enterprise Value over EBITDA regressed destribution of quarterly values had mean deviationof 24.87 and mean square error of  623.45. Chemocentryx Interest Expense is most likely to increase significantly in the upcoming years. The last year's value of Interest Expense was reported at 2.64 Million. The current Selling General and Administrative Expense is estimated to increase to about 45.5 M, while Consolidated Income is projected to decrease to (56.8 M).

Search Historical Trends 

 
Refresh
Check Chemocentryx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Chemocentryx main balance sheet or income statement drivers, such as Gross Profit of 54.5 M, Interest Expense of 2.9 M or Operating Expenses of 98.9 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0482, PPandE Turnover of 4.86 or Receivables Turnover of 446. Chemocentryx financial statements analysis is a perfect complement when working with Chemocentryx Valuation or Volatility modules. It can also supplement various Chemocentryx Technical models. Continue to the analysis of Chemocentryx Correlation against competitors.

Chemocentryx Quarterly Enterprise Value over EBITDA

(8.052)Share

Chemocentryx Enterprise Value over EBITDA Breakdown

Showing smoothed Enterprise Value over EBITDA of Chemocentryx with missing and latest data points interpolated. Measures the ratio between [EV] and [EBITDAUSD].Chemocentryx's Enterprise Value over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Chemocentryx's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value over EBITDA10 Years Trend
Decreasing
Slightly volatile
 Enterprise Value over EBITDA 
Share
      Timeline 

Chemocentryx Enterprise Value over EBITDA Regression Statistics

Arithmetic Mean(23.00)
Coefficient Of Variation(141.69)
Mean Deviation 24.87
Median(9.99)
Standard Deviation 32.59
Sample Variance 1,062
Range 103.00
R-Value(0.68)
Mean Square Error 623.45
R-Squared 0.47
Significance 0.014362
Slope(6.17)
Total Sum of Squares 11,686

Chemocentryx Enterprise Value over EBITDA History

2013 (5.95) 
2014 (5.93) 
2015 (7.32) 
2016 (8.58) 
2017  14.89 
2018 (14.96) 
2019 (44.26) 
2020 (85.85) 
2021 (88.11) 

About Chemocentryx Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Chemocentryx income statement, its balance sheet, and the statement of cash flows. Chemocentryx investors use historical funamental indicators, such as Chemocentryx's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although Chemocentryx investors may use each financial statement separately, they are all related. The changes in Chemocentryx's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Chemocentryx's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Chemocentryx Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Chemocentryx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Enterprise Value over EBITDA(85.85) (88.11) 
Enterprise Value4.3 B4.6 B
Tangible Asset Value518.9 M559.9 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-49.9 M-51.3 M
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California. Chemocentryx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Chemocentryx without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Earnings Calls Now

   

Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module

Pair Trading with Chemocentryx

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemocentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemocentryx will appreciate offsetting losses from the drop in the long position's value.

Chemocentryx Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Chemocentryx and Dynavax Technologies. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Chemocentryx Correlation against competitors. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.